ea0096oc2 | Section | UKINETS2023
Rzeniewicz Karolina
, Ward Caroline
, Khan Sairah
, Naik Mitesh
, Barwick Tara
, Aboayge Eric
, Sharma Rohini
Background: Peptide-receptor-radionuclide-therapy (PRRT) improves progression free survival in metastatic neuroendocrine neoplasia (NEN). To be suitable for PRRT, somatostatin receptor-2 (SSTR2) must be present on tumour site as determined by positive uptake on [68Ga]Ga-DOTA-peptide-PET/CT. LANTana is an ongoing study evaluating whether treatment with the demethylating agent, ASTX727, results in re-expression of SSTR2, as determined by [68Ga]Ga-DOTA-peptide-PE...